DiaMedica Therapeutics Inc. - DMAC STOCK NEWS

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the FDA has maintained the clinical hold on its ReMEDy2 Phase 2/3 trial for acute ischemic stroke treatment. This decision was due to a need for additional non-clinical data related to intravenous infusion materials. The company is preparing further in vitro studies to address FDA concerns and will request a Type A meeting for guidance. As of September 30, 2022, DiaMedica reported a cash balance of $36.1 million, reflecting a reduced cash burn of $2.3 million in Q3 2022. A conference call is scheduled for October 27, 2022, to discuss the update.

DiaMedica Therapeutics has appointed Julie VanOrsdel Daves as Senior VP of Clinical Development Operations, enhancing its leadership team as it prepares to resume enrollment in the ReMEDy2 acute ischemic stroke trial. Ms. Daves brings nearly 20 years of experience in clinical development, which includes pivotal Phase 3 programs. In connection with her appointment, she received a stock option grant for 140,000 shares at $1.47 each. DiaMedica's DM199, a recombinant form of KLK1, addresses significant medical needs in acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has announced that CEO Rick Pauls will participate in Lake Street Capital Market's 6th Annual Best Ideas Growth (BIG6) Conference in New York on September 14, 2022. The company, focused on developing treatments for neurological and kidney diseases, aims to improve the lives of patients with serious conditions through its lead candidate, DM199, a new treatment for acute ischemic stroke and chronic kidney disease. Investors can schedule one-on-one meetings with management during the conference.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) provided a business update and financial results for Q2 2022, highlighting a clinical hold on its Phase 2/3 ReMEDy2 trial for acute ischemic stroke due to transient hypotension events. The company plans to submit a proposal to the FDA in September to lift the hold, suggesting a modified dosing regimen. Financially, DiaMedica reported cash and investments of $38.4 million with a net loss impacting operating cash flow. R&D expenses decreased to $3.9 million for the six months ended June 30, 2022, while G&A expenses rose to $3.0 million.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced it will release its second quarter 2022 financial results on August 10, 2022, after market close. A live conference call is scheduled for August 11, 2022, at 7:00 AM CT to discuss the results and provide a business update. The company is focused on developing novel treatments for neurological disorders and kidney diseases, with its lead candidate, DM199, aimed at treating acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced participation in one-on-one meetings at the upcoming BTIG Biotechnology Conference on August 8-9, 2022, held at the St. Regis New York Hotel and virtually. The company focuses on developing treatments for neurological and kidney diseases, with its lead candidate DM199 being a recombinant form of the human tissue kallikrein-1 protein. Interested attendees can schedule meetings through their BTIG representatives. For further information, visit www.diamedica.com.

DiaMedica Therapeutics (NASDAQ: DMAC) has announced a clinical hold on its Phase 2/3 ReMEDy2 trial for DM199, aimed at treating acute ischemic stroke (AIS) patients. This hold follows the submission of serious adverse event reports related to transient hypotension in three patients after initial dosing. The company attributes these incidents to a change in IV bag materials used compared to prior trials and is working with the FDA to modify the trial protocol. Despite the setback, DiaMedica remains confident in DM199's potential for improving stroke outcomes.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. The company, focused on developing treatments for neurological disorders and kidney diseases, will hold one-on-one meetings with investors during the virtual event. DiaMedica's lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein, aimed at treating acute ischemic stroke and chronic kidney disease. For more information, visit www.diamedica.com.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has announced an expansion of its clinical study sites for the Phase 2/3 ReMEDy2 trial on DM199, treating acute ischemic stroke. The company currently has 9 active sites, more than double that of March 2022. However, site activation and patient enrollment have been slower than expected due to COVID-19-related staffing issues. Financially, DiaMedica reported a decrease in total cash and investments to $41.0 million as of March 31, 2022, down from $45.1 million in December 2021. Conference call scheduled for May 5, 2022.